STAT: 48-Wk Results for a Rapid Test-and-Treat Approach Using DTG/3TC in Newly Diagnosed Adults With HIV

September 29 - October 3, 2021; Virtual
Pilot study results support feasibility as first-line therapy in a test-and-treat setting, including in patients with a high HIV-1 RNA at baseline (ie, >500,000 copies/mL).
Format: Microsoft PowerPoint (.ppt)
File Size: 672 KB
Released: October 3, 2021

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue